Pharmacokinetic profile and effect on the faecal microbiome of a single dose of pradofloxacin oral suspension in the rabbit (Oryctolagus cuniculus)

2021 ◽  
Author(s):  
Shangzhe Xie ◽  
Darren J. Trott ◽  
Sugiyono Saputra ◽  
Esmaeil Ebrahimie ◽  
Manijeh Mohammadi Dehcheshmeh ◽  
...  
Keyword(s):  
Single Dose ◽  
Oryctolagus Cuniculus ◽  
Pharmacokinetic Profile ◽  
Oral Suspension ◽  
Faecal Microbiome

scholarly journals The tablet formulation of posaconazole: clinical pharmacology and the use in patients with hematologic malignancies

2020 ◽  
Vol 22 (2) ◽  
pp. 96-117
Author(s):  
Alexander V. Veselov
Keyword(s):  
Clinical Studies ◽  
Fungal Infections ◽  
Plasma Concentrations ◽  
Pharmacokinetic Profile ◽  
Hematologic Malignancies ◽  
Tablet Formulation ◽  
Oral Suspension ◽  
Tolerability Profile ◽  
Hematopoietic Stem ◽  
Release Tablet

Posaconazole is a broad-spectrum triazole antifungal agent with potent activity against various fungi, including yeast and molds, including Mucorales, what makes a key difference with itraconazole and voriconazole. Clinical studies have demonstrated his efficacy for prophylaxis against invasive fungal infections in hematological patients at high risk (with acute myeloid leukemia, myelodysplastic syndrome, aplastic anemia, and in patients after hematopoietic stem cell transplantation, especially with graft versus host disease). Posaconazole also use as salvage therapy against invasive aspergillosis, mucormycosis and some other systemic mycoses. For today there are 3 posaconazole formulations – oral suspension, modify release tablet and intravenous solution (not registered in Russia at the time of writing this paper). As far as bioavailability of posaconazole following administration by oral suspension is highly variable with low unstable plasma concentrations and there are number of factors with negatively influence to the pharmacokinetic profile of suspension a delayed-release tablet was developed using hot-melt extrusion technology with a pH-sensitive polymer. The tablet formulation releases the drug in the intestine, and this leads to the enhanced bioavailability and increased posaconazole exposure parameters and, as a result, to a higher efficacy. This was demonstrated in pre-clinical, early phase clinical studies and confirmed with data from real practice. The tablet formulation has well tolerability profile with a low incidence of clinically significant adverse events. For today posaconazole included in all relevant clinical recommendations with high levels of evidence, including prophylaxis of invasive mycoses and therapy of their refractory forms, while the authors agree that for the oral therapy a preference should be given to the tablet formulation of posaconazole.

Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): Single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects

2009 ◽  
Vol 31 (2) ◽  
pp. 399-410 ◽  
Author(s):  
Jose Antonio Palma-Aguirre ◽  
Jorge Villalpando-Hernández ◽  
Germán Novoa-Heckel ◽  
Iván Oliva ◽  
Lizbeth Cariño ◽  
...  
Keyword(s):  
Single Dose ◽  
Naproxen Sodium ◽  
Oral Suspension ◽  
Open Label ◽  
Oral Tablet

scholarly journals Pharmacokinetic profile and metabolite identification of bornyl caffeate and caffeic acid in rats by high performance liquid chromatography coupled with mass spectrometry

RSC Advances ◽  
2019 ◽  
Vol 9 (7) ◽  
pp. 4015-4027 ◽  
Author(s):  
Baimei Shi ◽  
Lingjian Yang ◽  
Tian Gao ◽  
Cuicui Ma ◽  
Qiannan Li ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
High Performance Liquid Chromatography ◽  
Liquid Chromatography ◽  
Single Dose ◽  
Metabolic Profile ◽  
High Performance ◽  
Ion Trap ◽  
Metabolite Identification ◽  
Pharmacokinetic Profile ◽  
Tof Ms

We revealed the metabolic profile of bornyl caffeate by HPLC-Q-TOF/MS, and then simultaneously examined the pharmacokinetics of bornyl caffeate and CA after administration of a single dose of bornyl caffeate by HPLC ion trap MS.

Single-Dose Pharmacokinetics of Amphetamine Extended-Release Oral Suspension in Healthy Adults

2019 ◽  
pp. 108705471984113
Author(s):  
Barry K. Herman ◽  
Mohammed Bouhajib ◽  
Thomas R. King ◽  
Judith C. Kando ◽  
Antonio Pardo
Keyword(s):  
Single Dose ◽  
Extended Release ◽  
Healthy Adults ◽  
Oral Suspension
Sign in / Sign up

Export Citation Format

Share Document